The MRE11, RAD50, and NBS1 genes encode proteins of the MRE11-RAD50-NBS1 (MRN) complex critical for proper maintenance of genomic integrity and tumour suppression; however, the extent and impact of their cancer-predisposing defects, and potential clinical value remain to be determined. Here, we report that among a large series of approximately 1000 breast carcinomas, around 3%, 7% and 10% tumours showed aberrantly reduced protein expression for RAD50, MRE11 and NBS1, respectively. Such defects were more frequent among the ER/PR/ERBB2 triple-negative and higher-grade tumours, among familial (especially BRCA1/BRCA2-associated) rather than sporadic cases, and the NBS1 defects correlated with shorter patients' survival. The BRCA1-associated and ER/PR/ERBB2 triple-negative tumours also showed high incidence of constitutively active DNA damage signalling (gH2AX) and p53 aberrations. Sequencing the RAD50, MRE11 and NBS1 genes of 8 patients from non-BRCA1/2 breast cancer families whose tumours showed concomitant reduction/loss of all three MRN-complex proteins revealed two germline mutations in MRE11: a missense mutation R202G and a truncating mutation R633STOP (R633X). Gene transfer and protein analysis of cell culture models with mutant MRE11 implicated various destabilization patterns among the MRN complex proteins including NBS1, the abundance of which was restored by re-expression of wild-type MRE11. We propose that germline mutations qualify 
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Introduction
The MRN complex, consisting of MRE11, RAD50 and NBS1 proteins, plays multiple roles in the maintenance of genome integrity, including detection and signalling of DNA damage, processing the DNA lesions and participation in cell cycle checkpoints, DNA replication and repair, as well as induction of cellular senescence or cell death (Trenz et al., 2006; Stracker et al., 2004; Lukas et al., 2004b; Rupnik et al., 2008) . In response to DNA double strand breaks (DSB), the MRN complex serves as the sensor of DNA breakage, and recruits and helps to activate the key signal transducer of the DNA damage response (DDR) machinery, the ATM kinase Uziel et al., 2003; Carson et al., 2003; Cerosaletti et al., 2006; Horejsi et al., 2004; Falck et al., 2005; Shiloh, 2006; Lavin, 2007) . The MRE11 protein can bind DNA, possesses both exonuclease and endonuclease activities, and provides the bridge between NBS1 and RAD50 (Stracker et al., 2004; Rupnik et al., 2008) . RAD50 dimerizes and uses its long coiled-coil ''arms'' to hold the ends of broken DNA together. The NBS1 protein itself has no enzymatic activity but mediates several protein-protein interactions that help the MRN complex to perform its many functions. Among the direct interactors of NBS1 are the ATM kinase itself (Falck et al., 2005) , the MDC1 adaptor protein (Goldberg et al., 2003; Lukas et al., 2004a) and CtIP, a tumour suppressor protein that promotes processing of the DSBs by MRN (Sartori et al., 2007) , an effect which facilitates activation of the ATR-Chk1 signalling cascade and homologous recombination repair (Adams et al., 2006; Jazayeri et al., 2006; Sartori et al., 2007; Cimprich and Cortez, 2008) . Overall, the functions of the MRN complex prevent excessive DNA breakage and genomic instability, thereby preventing genetic diseases including cancer. The physiological significance of the MRN complex is apparent from the pathological conditions caused by mutations of the respective genes. Germline homozygous mutations in NBS1 and MRE11 cause rare autosomal disorders Nijmegen breakage syndrome (NBS) and ataxia telangiectasia-like disorder (A-TLD), respectively (Varon et al., 1998; Stewart et al., 1999) . Analogous to the more frequent ataxia telangiectasia (A-T), a severe multifaceted disease caused by mutations of ATM, the NBS and A-TLD patients are tumour prone, and their cells display radiosensitivity, checkpoint defects, and genetic instability (Shiloh, 2006; Lavin, 2007) . The link between defects of the MRN complex and cancer is also apparent from aberrations of Mre11, NBS1 and RAD50 identified in some types of sporadic tumours (Giannini et al., 2002 (Giannini et al., , 2004 Angele et al., 2003; Lu et al., 2006) , as well as the phenotypes of mice with hypomorphic mutations of NBS1, for example (Stracker et al., 2004 (Stracker et al., , 2007 .
The intimate involvement of the DDR machinery in cancer pathogenesis and response to treatment is apparent from the fact that diverse components of DNA damage signalling, checkpoints and repair pathways are commonly deregulated in cancer, and their status may also dictate the response to genotoxic therapies including ionizing radiation and diverse chemotherapeutics Zhou and Bartek, 2004) . In addition, the ATM/MRN-coordinated DDR network is often constitutively activated in various types of human cancer, already at the early, preinvasive stage (Bartkova et al., 2005a; Gorgoulis et al., 2005) . This phenomenon appears to reflect endogenous oncogene-induced replication stress and DNA breakage in the tumour cells (Bartkova et al., 2005a (Bartkova et al., , 2006 Gorgoulis et al., 2005; DiMicco et al., 2006) , suggesting that the DDR network may provide an intrinsic barrier against cancer progression (Halazonetis et al., 2008; . This concept furthermore implies that the activated DDR barrier creates growth-suppressive conditions under which inactivating aberrations within the DDR machinery, such as those in ATM, MRN complex or p53 are likely selected for, to allow the early lesions to overcome the DDR-induced senescence and/or cell death pathways and progress towards full malignancy Halazonetis et al., 2008) .
Inspired by these recent advances, as well as by the suggestion of germline variants in NBS1 and RAD50 as putative cancer susceptibility mutations for both gastrointestinal tumours (Ebi et al., 2007) and breast cancer (Gó rski et al., 2003; Heikkinen et al., 2006; Tommiska et al., 2006) , we designed this project to address the following specific issues: (i) What is the extent of the MRN complex defects in familial breast cancer? (ii) Are there any germline heterozygous mutations in Mre11 that might predispose to familial breast cancer? If so, what effect do such Mre11 variants have on the other proteins of the MRN complex? (iii) Do the potential MRN aberrations correlate with any clinicopathological features of the tumours or with survival of the breast cancer patients? (iv) Finally, is there evidence for the DDR machinery, including MRN, playing a role of the intrinsically activated anti-cancer barrier also in familial cancer, analogous to sporadic solid tumours? In an effort to address these questions, we combined immunohistochemical and genetic analyses of a large series of breast carcinomas from patients with known clinicopathological parameters and familial versus sporadic history, complemented by experiments with cell culture models with defined genetic defects of NBS1 and MRE11.
Results

Aberrant expression of the MRN complex proteins in breast cancer
To assess the expression of the Mre11, Rad50 and Nbs1 proteins in a large cohort of around 1000 breast carcinomas, we employed immunohistochemistry on tissue arrays, using specific antibodies against each of the three proteins. Compared to patterns seen in normal breast tissue, the expression of each of the three MRN-complex proteins was considered normal in the majority of the tumours ( Figure 1) ; however, aberrantly reduced or lost expression was apparent in a significant proportion of the cases (Figures 2, 3 and Table 1 ). Table 1 presents the results in the three subcategories of deficient expression of a particular protein: (i) reduction of the staining intensity in cancer cells; (ii) reduction of the percentage of positive carcinoma cells; or (iii) defective expression manifested as concomitant loss of staining intensity and lower percentage of positive carcinoma cells in a given lesion (see also Section 4 for details of the scoring criteria). As can be seen from the examples of immunohistochemical staining shown in Figures 1-3 , deficient expression in a given tumour could be either selective for one of the MRN-complex proteins, especially NBS1 (Figure 2 ), or such aberrant reduction could be seen concomitantly, even for all three proteins in the same tumour (Figure 3 ). The overall data in Table 1 also demonstrate that the protein most frequently affected was NBS1 (deficient in over 10% carcinomas), followed by MRE11 (around 7% aberrant cases) and RAD50 (only some 3% of aberrations).
Parallel immunohistochemical examination of phosphorylated histone H2AX (gH2AX), an established marker of activated DDR machinery, revealed a wide range of Figure 1 -Immunoperoxidase detection of MRN complex proteins and gH2AX in normal human breast and breast carcinomas. Normal human breast tissue shows strong nuclear positivity for all three proteins of the MRN complex: Mre11, Rad50 and Nbs1, while the staining for the DNA damage signalling marker gH2AX is negative. The two examples of invasive breast carcinomas shown in the middle and right-hand columns also express the three MRN complex proteins, and the cancer cells are heterogeneously positive for the gH2AX marker, indicating ongoing DNA damage signalling. positivity, from highly positive to virtually negative cases among the breast tumours, in sharp contrast to consistent lack of gH2AX staining in normal breast tissues (see bottom panels in Figures 1-3 ). These findings indicated ongoing signalling from the DNA damageresponsive PIKK-family kinases in a substantial proportion of invasive carcinomas, a phenomenon the potential significance of which is discussed later, relative to other parameters of the tumours. Collectively, these results indicated that aberrantly reduced or lost expression of the individual proteins of the MRE11-RAD50-NBS1 complex, and constitutive activation of the upstream DDR signalling, are characteristic features of significant subsets of human breast carcinomas.
2.2.
MRN status in sporadic versus familial, especially BRCA1/2-related tumours
The intriguing variation in the respective frequencies of defective expression among the three MRN-complex proteins, and the availability of clinical specimens from both sporadic and familial breast tumours, led us to consider potential differences between sporadic and familial cases. Data in Table 1 demonstrate that indeed, there was an overall trend for the MRN protein defects to occur more frequently among familial breast carcinomas. This trend was most apparent for the RAD50 aberrations among patients from families with three or more affected family members ( p ¼ 0.02; when compared with sporadic cases). The most striking result, however, was the pronounced, statistically highly significantly enhanced incidence of the MRNaberrant tumours among the familial breast cancers linked to carriers of BRCA1 and BRCA2 mutations, as compared to all non-BRCA1/2 tumours (Table 1 and Figure 4A ,C). This feature was most apparent for the BRCA1-tumours, with the statistical significance at p values: p < 0.0000001, p ¼ 0.006 and p ¼ 0001 for RAD50, NBS1 and MRE11 defects, respectively. While the frequency of RAD50 aberrations among BRCA2-tumours was very similar to BRCA1-cases, with high statistical significance as compared to nonBRCA1/2 tumours, it was less apparent for the NBS1 and MRE11 proteins (Table 1 and Figure 4A ). The potential biological basis of such enhanced occurrence of MRNcomplex aberrations among breast carcinomas of the familial, particularly BRCA1/2-related origin, is considered in Section 3.
MRN defects, histopathological features and survival
Histopathological features of the nonBRCA1/2 tumours with normal and aberrant MRN protein expression are shown in Table 2 . The tumours with reduced MRN expression were Rad50 and Mre11 (variable) , as shown at low (left) and high (right) magnification. Note the preserved nuclear staining for Nbs1 in the scattered stromal cells within the tumour, contrasting with virtually negative cancer cells. This tumour shows moderate yet detectable (heterogeneous) staining for the gH2AX marker, visible as foci in some nuclei at the higher magnification. significantly more often oestrogen receptor (ER) negative, progesterone receptor (PR) negative and of higher grade than the tumours with normal MRN expression. No association between aberrant MRN expression and ERBB2 alone was seen; however, the MRN-aberrant tumours were significantly more frequently ER/PR/ERBB2-triple-negative than the MRN normal tumours (Table 2 and Figure 4B ). The tumours with reduced RAD50 expression also tended to be more often of ductal histology than the tumours with normal RAD50 expression. For other parameters studied (TNM stage, p53 expression), the tumours showing aberrant or normal MRN expression did not differ significantly, although the RAD50 and NBS1 aberrant tumours showed a tendency of being more often p53 immunopositive (likely mutant for p53) than the RAD50 and NBS1 normal tumours ( p ¼ 0.03 and p ¼ 0.06, respectively).
Histopathological features of BRCA1 and BRCA2 tumours with normal and aberrant MRN expression were also considered. No specific characteristics differentiating MRN-aberrant BRCA1 or BRCA2 tumours were seen, despite a slight tendency of MRN-deficient expression to be associated with ER and/or PR negativity. Overall, however, the number of tumours in the BRCA1 and BRCA2 groups is probably too small to reveal any statistical differences (negative data, not shown).
In terms of the clinical outcome and MRN status of the tumours, there was no significant difference in survival of the patients between normal and reduced RAD50 and MRE11 subgroups (data not shown); the patients with NBS1-aberrant tumours, however, seemed to have poorer survival than the patients with NBS1 normal tumours ( p ¼ 0.0028, Figure 4D ).
2.4.
Germline mutations of MRE11 in breast cancer families
The recent suggestion of germline variants of NBS1 and RAD50 as breast cancer-predisposing mutations (Gó rski et al., 2003; Heikkinen et al., 2006; Tommiska et al., 2006) , and our findings of aberrant reduction or loss of the MRN complex proteins in familial breast tumours in this study, led us to examine the sequence of all three MRN complex genes for potential germline mutations. First, genomic DNA isolated from blood cells of eight patients with tumours showing the concomitant aberrant expression of all three MRN complex proteins was sequenced to search for mutations in the coding regions and intron-exon boundaries of RAD50, NBS1 and MRE11. This analysis identified two putatively disease-associated sequence variants in MRE11: c.604 A>G (Arg202Gly) missense mutation in exon 7 and c.1897 C>T (Arg633STOP) nonsense mutation in exon 17, each mutation in a patient from a different family. All the variants found in NBS1 and RAD50 were common polymorphisms and intronic variants, and the overall data from these sequencing analyses of this series can be provided upon request. In addition to the sequencing of all three genes in the patients with MRN-triple-defective tumours, the coding sequence and intron-exon boundaries of the NBS1 gene of seven additional patients, this time those with tumours aberrant for only NBS1 protein expression, were analysed using conformation sensitive gel electrophoresis (CSGE). Genomic DNA from cases showing mobility shifts on CSGE was bidirectionally sequenced. Only the same common variants were found as in the patients screened for all three genes (Table 3) .
Since germline mutations in the MRE11 gene have so far not been identified in breast cancer families, we then focused on a closer analysis of the two mutations found in our present study. The positions of these alterations relative to the functional domains of the MRE11 protein are shown in the schematic representation in Figure 5A . Either mutation was then screened for among additional 332 patients with strong family history of breast cancer, as well as among 363 healthy female control subjects from the same geographical region. Neither mutation was found in the additional 332 familial breast cancer patients, and while the MRE11 
Arg202Gly mutation was present in 1/363 population controls, the MRE11 Arg633STOP mutation was absent in the normal population controls. Although the MRE11 Arg202Gly may be a rare polymorphism with uncertain effect on breast cancer pathogenicity, bioinformatics analysis revealed the SIFT score 0.02 (<0.05 intolerant) for this point mutation, and PolyPhen indicated that it is ''probably damaging'' to the resulting protein. The likely pathogenic impact of the truncating mutation MRE11 Arg633STOP became apparent from the fact that in its homozygous state, the same mutation was already reported as the genetic basis in a family suffering from the A-TLD syndrome, a very rare condition with severe neurological and genome instability features (Stewart et al., 1999) . Importantly from the point of view of this study, both of these identified MRE11 mutations are associated with aberrant reduction or loss of not only the MRE11 protein itself, but also the other proteins of the MRN complex. This is documented for the MRE11 Arg633STOP mutant in the lower part of Figure 5A , showing the virtual absence of all three MRN complex proteins in the tumour cells. The fact that all three MRN proteins are still detectable in the normal stromal cells within the tumours, while selectively absent in the cancer cells ( Figure 5A ) is consistent with the heterozygous germline mutation (carrier state) of MRE11 in the respective patients, and the subsequent silencing or loss of the second allele only in the tumour.
To find out what additional tumours possibly occurred among the members of the family of the patient carrying the clearly pathogenic MRE11 Arg633STOP mutation, data from five generations were collected. As can be seen from the pedigree diagram in Figure 5B , apart from the three breast tumours among the close relatives, there were multiple cases of other types of malignancies among maternal relatives of the patient (proband) who carries the germline MRE11 mutation. 
2.5.
MRN complex proteins in cultured cells with mutant vs. wild-type MRE11
Stimulated by our observations of a wide spectrum of MRN complex protein abnormalities seen in clinical material by immunohistochemistry (Section 2.1), we next turned to cell culture models to search for analogous patterns and to gain some insight into the phenomenon of one or more MRN complex proteins being aberrantly reduced or apparently absent. For the scenario of a selective defect of only NBS1, we first used immortalized fibroblasts (NBS-tert) and lymphoblasts (NBS-1LBI) established from patients suffering from the NB syndrome caused by NBS1 mutations. As can be seen in Figure 6A , whereas the total level of endogenous NBS1 protein was either very low (in the NBS-1LBI lymphoblasts) or undetectable (NBS-tert fibroblasts) in such cells, the abundance of the other proteins of the MRN complex, Rad50 and MRE11, was apparently unaffected and comparable to both control normal diploid BJ fibroblasts and MRN-proficient U2OS cells. In addition, in both, NBS1-defective fibroblasts and lymphoblasts reconstituted to express wild-type NBS1, the overall abundance of MRE11 and RAD50 proteins remained unchanged, despite the overexpression of ectopic wild-type NBS1 ( Figure 6A ). Finally, selective abnormalities of NBS1 are not restricted to cells from NB syndrome patients, as can be seen from an analogous NBS1-restricted protein deficiency in the human colon cancer cell line HT29 ( Figure 6A ).
Given the focus of this study on MRE11 aberrations, we next examined the fibroblasts from the reported patients with the A-TLD syndrome, referred to as A-TLD1, A-TLD2 and A-TLD3 cells in the literature (Stewart et al., 1999) . Importantly, while the homozygous MRE11 mutation present in A-TLD1 and A-TLD2 cells is the R633X truncating mutation, identical with the germline heterozygous mutation that we identified in this study in a breast cancer family, the mutation in A-TLD3 cells is only a point missense mutation (c. 350 A>G; Asn117Ser) which is also consistent with milder clinical features of the A-TLD3 patient compared with A-TLD1/2 (Stewart et al., 1999) . Consistent with the previous analyses of the MRE11, RAD50 and NBS1 proteins in these cells (Stewart et al., 1999; Uziel et al., 2003) , we found gross down-regulation or absence of all three MRN complex proteins in the A-TLD1 and A-TLD2 cells, in contrast to only mild reduction of the overall protein levels of NBS1 and RAD50 in the A-TLD3 cells ( Figure 6B ). The homozygous mutation MRE11 R633X in A-TLD1 and A-TLD2 cells destabilizes all three MRN proteins, and reconstitution of wild-type MRE11 capable of forming proper interactions with the endogenous RAD50 and NBS1 in these cells led to recovery of normal protein levels also for RAD50 and NBS1 (Stewart et al., 1999; Uziel et al., 2003) . To further characterize the impact of the homozygous MRE11 R633X mutation at the cellular level, we examined the immunofluorescence staining patterns of all three MRN complex proteins in the A-TLD2 cells, as well as their ability to respond to moderate doses of ionizing radiation in terms of the gH2AX foci formation. As can be seen from the confocal microscopy images shown in Figure 7 , the endogenous MRE11 and RAD50 proteins were essentially undetectable, while the NBS1 protein was barely detectable and/or mislocalized to cytosol. These aberrant patterns strongly contrasted with the nuclear staining for each of the MRN complex proteins in control human cells (Figure 7) . Despite the gross defect of the MRN complex, however, irradiation of the A-TLD2 cells still led to histone H2AX phosphorylation, as deduced from the focal staining for gH2AX at one hour post irradiation (Figure 7) . The implications of these findings for our data obtained with clinical material, as well as conceptual issues of DNA integrity maintenance are considered below (see Sections 2.6 and 3).
Thus, whereas MRE11 mutations such as the R633X seen in the A-TLD1, A-TLD2 and one breast cancer family in our present study can account for the concomitant loss of all three MRN complex proteins, it is presently unclear whether some other types of MRE11 mutations might selectively affect the protein level of just one of the MRN complex proteins. This speculative possibility is especially attractive considering our finding of a larger fraction of NBS1 protein-selective defects compared with RAD50 or MRE11 protein aberrations (see Section 2.1), and the fact that at least at the germline DNA level, our sequencing efforts did not identify NBS1 gene mutations that would explain the aberrantly reduced expression of only NBS1 in the selected cases (see Section 2.4). To test the potential effect of MRE11 mutation on NBS1 level experimentally, we examined the human HCT116 colon cancer cell line, very recently reported to harbour a mixture of wildtype MRE11 and a splice mutant MRE11 that leads to partial deletion of sequences in the N-terminal nuclease domain, also affecting the NBS1-interaction motif in this region of MRE11 (Wen et al., 2008) . While this mutant allele of MRE11 preserves some functions of the wild-type protein, and suppresses other functions of the MRN complex in a dominant negative manner, its potential impact on the abundance of the other proteins of the MRN complex was not investigated (Wen et al., 2008) . Interestingly, our Western blotting analysis of total cell lysates from HCT116 cells revealed detectable MRE11 
and RAD50 proteins, and a grossly reduced abundance of NBS1 ( Figure 6C ). Consistent with our hypothesis about potential selective destabilization of NBS1 in some MRE11-mutant cells, moderate ectopic expression of wild-type MRE11 in HCT116 cells rescued the aberrant NBS1 protein deficiency, resulting in close-to-normal levels of endogenous NBS1 ( Figure 6C ). Furthermore, the effect of ectopic wild-type MRE11 on NBS1 protein level was indistinguishable in both the p53-proficient and p53-deleted HCT116 cell variants, suggesting that loss of p53 function, a common event in both breast and colon cancer, with pleiotropic phenotypic effects, does not affect the impact of MRE11 status on NBS1 protein abundance ( Figure 6C ). Collectively, these results indicate that distinct mutations of MRE11 can cause aberrant reduction of MRN complex proteins, resulting in low expression of all three MRN proteins, or selective down-regulation of NBS1, for example. 
2.6.
DNA damage signalling and p53 status in subsets of familial breast cancer Our in vitro experiments indicated that DNA damage signalling, at least as judged from the ability to phosphorylate H2AX after genotoxic stress, can still be operational despite defects in the MRN complex (Figures 7) . In addition, previous studies reported frequent constitutive activation of the DNA damage checkpoints in human sporadic cancers and inactivation of various components of the DDR machinery, including p53 mutations, during cancer progression (DiTullio et al., 2002; Bartkova et al., 2005a; Gorgoulis et al., 2005; Bartkova et al., 2007) consistent with the proposed role of DDR as an inducible biological barrier against tumorigenesis Halazonetis et al., 2008) . To assess the ongoing constitutive DDR signalling and p53 status in relation to diverse subsets of human familial breast cancer, we scored the gH2AX marker and p53 overexpression by immunohistochemistry using previously validated antibodies and tissue arrays (see Section 4). Examples of the staining patterns for gH2AX are shown in Figures 1-4 , and ranged from negative staining in normal breast tissue and some carcinomas, up to strongly positive tumours. As can be seen from the summary graph in Figure 8A , between 30-60% of the breast tumours scored positive for the gH2AX marker indicative of active DNA damage signalling even before any DNA damaging chemo-or radiotherapy was initiated. Interestingly, while the highest proportion of the gH2AX-positive tumours was among the BRCA1-linked familial breast cancers (close to 60%), BRCA2-linked tumours showed the lowest proportion (30%), and the nonBRCA1/2 carcinomas were intermediate, with almost half of the cases positive for gH2AX. Another interesting finding was the highest proportion of gH2AX-positivity (close to 70% of cases) among the more aggressive, difficult-to treat ER/PR/ERBB2-negative carcinomas, compared to tumours with at least one of the hormonal receptors positive or showing overexpression of ERBB2 ( Figure 8B ).
Finally, p53 overexpression (indicative of p53 mutation) was most frequent among the ER/PR/ERBB2-triple negative tumours, followed by BRCA1-tumours, then nonBRCA1/2-familial tumours, and the lowest among BRCA2-tumours and hormone receptor positive carcinomas, thus following the same overall trend as the gH2AX marker for constitutive activation of the DDR (Figure 8A,B) . This result is consistent with the concept of the DDR machinery as an activator of p53 within the anti-cancer barrier network that becomes functionally disabled during cancer progression, as the overall proportion of p53 aberrations broadly correlated with the degree of constitutive DNA damage signalling.
Discussion
The results reported in this study can contribute in several ways to better understanding of the role(s) the MRN complex plays in human cancer in general, and in familial breast cancer in particular. First, our data show that apart from sporadic breast tumours ( Stewart et al., 1999) show only mild reduction of the Rad50 and Nbs1 protein abundance, compared to control normal human lymphoblasts (Nh-LB). Cdk7 was used to verify equal loading. (C) MRN complex protein expression is normal in the MRN-proficient colon cancer cell line SW620 (Giannini et al., 2002) , while the HCT116 cells show low levels of endogenous full-length Mre11 and a shorter dominantnegative splice variant of Mre11 (Wen et al., 2008 , and data not shown), with a strong impact on Nbs1 total abundance. Note that the level of endogenous Nbs1 is restored upon moderate expression of additional wild-type Mre11 in HCT116 cells, and independently of the p53 status. Detection for SMC1 served as a loading control.
that show aberrant reduction or loss of any of the three MRN complex proteins, either alone or combined in the same lesion. We show that such aberrations tend to be even more frequent among BRCA1 and BRCA2 mutation carriers (Figure 4 ). In addition, the MRN defects were more frequent among highergrade tumours and correlated with the lack of oestrogen and progesterone receptors, with an increased incidence especially among the so-called ER/PR/ERBB2-triple negative carcinomas. Whether such abnormalities in the DDR machinery contribute to the general treatment resistance of the ER/PR/ ERBB2-triple negative subset of breast tumours (Cleator et al., 2007) remains to be investigated; however, our present finding of the overall poorer survival of patients with NBS1-defective tumours is consistent with such possibility. Future work should establish whether certain pathways and components of the DDR machinery including the MRN complex are especially important for any particular subset of breast cancer cells defined by the new emerging markers, including those for the so-called breast cancer stem cells (Celis et al., 2007 and references therein), possibly linked with aberrant DNA Figure 7 -Immunofluorescence and confocal microscopy analysis of MRN complex proteins and g-H2AX in A-TLD2 and U2OS cells. Panels of images documenting nuclear expression of the indicated proteins (red signal) in control U2OS cells, in contrast to the lack of MRN protein expression in A-TLD2 cells with the homozygous Mre11 R633X mutation. Parallel DNA staining (DAPI, blue) and immunocytochemical staining for 53BP1 served to visualize nuclei and provide a positive protein control, respectively. The lower panels show a preserved ability to form the g-H2AX foci at 1 h after 4 Gy of ionizing radiation (IR) also in the A-TLD2 cells.
damage signalling or repair and the apparent enhanced treatment resistance of such cells. Second, our genetic analysis of a subset of patients with MRN protein-defective tumours identified two germline heterozygous mutations of MRE11 that are associated with down-regulation of all three MRN complex proteins, and likely accompanied by the loss of the second allele of MRE11 in the tumour, as judged from the partially preserved expression of the MRN proteins in the surrounding stromal cells but selective lack of expression in tumour cells (see e.g. Figure 5A ). The ''pathogenic'' nature of the truncating MRE11 R633X mutation is apparent as the germline homozygous state of the same mutation causes severe immunodeficiency, neurological symptoms and chromosome instability features associated with the A-TLD syndrome (Stewart et al., 1999) . The disease association of the R202G missense change is less clear, yet it may also undermine the tumour suppressor function of MRE11 since the expression of whole complex was aberrantly reduced, and bioinformatics analysis indicated the amino acid substitution being potentially harmful for the structure, and hence the function of Mre11. Since the same patient also harbours the moderately breast cancerpredisposing c.1100delC variant of the ATM-activated Chk2 kinase (also referred to as CHEK2; Vahteristo et al., 2002) it is plausible to speculate that the two heterozygous germline mutations might have both contributed to cancer development. MRE11 operates both upstream of Chk2 (in DNA damage signalling; Shiloh, 2006; and in parallel with Chk2 (in the S-phase checkpoint; Falck et al., 2002) , and the concomitant occurrence of the two mutations in the same patient's germline would be expected to cooperatively increase the likelihood of breast cancer development. In the other six patients whose germline DNA did not reveal any MRN gene mutations, the tumour-associated lower expression of the MRN complex proteins might reflect somatic mutations or epigenetic changes in the MRN genes themselves or their regulators. Overall, as we found two distinct germline mutations of MRE11 among the eight tested patients with nonBRCA1/2 familial breast cancer, MRE11 may be suggested as a new candidate to the list of breast cancer-predisposing genes, the majority of which participate in the DNA damage response network (Walsh and King, 2007) . In fact, we suggest that the MRE11-R633X mutation, and possibly other MRN gene mutations, may predispose to a wider spectrum of malignancies than just breast cancer. Such a possibility is supported by some recent data on cancer-predisposing NBS1 mutations (Ebi et al., 2007; Seemanová et al., 2007) , by the critical genome maintenance role of MRN in a wide spectrum of cell types (Stracker et al., 2004; Lavin, 2007) , as well as by our present data on the broad range of malignancies in the family of the patient with the R633X mutation ( Figure 5B ) and the known involvement of mutations in ATM and CHEK2 (two genes whose products are functionally intimately linked with the MRN complex) in both breast cancer and other types of tumours (Ahmed and Rahman, 2006; Nevanlinna and Bartek, 2006; Shiloh, 2006) . Finally, increased risk of breast cancer development has been suggested for individuals with certain singlenucleotide polymorphic variants in the MRN complex genes including MRE11 (Hsu et al., 2007) .
From a broader conceptual view, our data on MRE11 further support and extend the notion that products encoded by the established breast cancer susceptibility genes characterized so far (at least those that impose high or moderate risk of breast cancer development) operate in the genome maintenance network (Figure 9 ). The genes implicated in familial breast cancer predisposition, including MRE11 reported here, include all three components of the DNA damage-sensing MRN complex (Gó rski et al., 2003; Heikkinen et al., 2006 ; and this study), the DNA damage signalling kinases ATM (reviewed in Ahmed and Rahman, 2006) and Chk2 (reviewed in Nevanlinna and Bartek, 2006) , and several effectors of the DDR machineryd the pro-apoptotic p53 and caspase 8 (Cox et al., 2007) , and DNA repair proteins represented by the products of the prototypic breast cancer susceptibility genes BRCA1 and BRCA2 and their interactors BRIP1 and PALB2 (Erkko et al., 2007) , respectively (reviewed in Walsh and King, 2007) . The PTEN tumour suppressor impacts the DDR machinery through at least two mechanisms, by regulating the localisation of the checkpoint kinase Chk1 via the AKT kinase activity downstream of PTEN (Puc et al., 2005) , and by positive regulation of expression of the key homologous repair factor Rad51 , thereby modulating the Chk1-Rad51 pathway (Sørensen et al., 2005) and both cell cycle checkpoints and DNA repair (Figure 9 ). Unlike ATM and CHEK2, genes encoding the ATR and Chk1 DNA damagesignalling kinases have so far not been directly implicated in breast cancer susceptibility in terms of germline mutations (Figure 9) , possibly reflecting the fact that the latter, but not the former two genes are essential for embryonic development and viability Cimprich and Cortez, 2008) . For example, apart from its non-essential signalling role after genotoxic insults, the Chk1 kinase has also important roles in regulating normal S phase (Sørensen et al., 2003) and mitotic entry (Krä mer et al., 2004) , and Chk1 inhibition under normal unperturbed cell cycle conditions leads to rapid destabilisation of the genome and proliferation blockade or cell death (Syljuasen et al., 2005) . On the other hand, it cannot be excluded that haploinsufficiency or hypomorphic mutations of ATR and/or Chk1 might still be identified in rare breast cancer families in the future. In fact, the breast cancerpredisposing genetic factors remain still unknown for a large fraction of familial breast cancers, and it is likely that other components of the genome maintenance machinery will turn out to account for at least some of the familial breast cancer susceptibility.
Another issue conceptually relevant to this study is the constitutive activation of the DDR machinery (monitored here by gH2AX), consistent with the proposed concept of Figure 9 -Schematic illustration of the roles of the known breast cancer susceptibility genes within the DNA damage response network. The 12 breast cancer susceptibility genes with known functions share the involvement of their protein products in the genome maintenance network, operating at various levels from sensing the DNA lesions (the MRN complex), through transducing the damage signal (ATM and Chk2), up to effector roles in DNA repair, checkpoint or cell death pathways (blue arrows). The previously reported breast cancer susceptibility genes are marked in yellow, the new candidate reported in this study (Mre11) in red, and the essential genes ATR and Chk1 that may contribute to tumorigenesis through haploinsufficiency in white. The PTEN tumour suppressor regulates DNA damage signalling and repair through regulation of Chk1 and Rad51 (dashed arrows), and Rad51 (shown in grey) might be a cancer susceptibility gene itself (see Section 3 for more details).
DNA damage checkpoint activation as an inducible biological mechanism to delay or prevent tumour progression (Bartkova et al., 2005a; Gorgoulis et al., 2005; Halazonetis et al., 2008) . Previous reports documented activated Chk2 (DiTullio et al., 2002) and 53BP1 in fractions of invasive sporadic breast carcinomas, and preferential activation of the DDR machinery in early, preinvasive lesions (Bartkova et al., 2005a; Gorgoulis et al., 2005) including carcinoma in situ of the breast. Here we show that defects of the MRN complex can also occur already at the preinvasive carcinoma in situ stage (Figure 2) , and that gH2AX, an established marker of DDR signalling, is commonly detectable also among familial breast tumours. The highest incidence of gH2AX-positive cases was identified in the BRCA1-associated familial tumours, and the ER/PR/ERBB2-triple-negative subset of breast carcinomas. Most significantly, the frequency of gH2AX-positive cases in different subsets of breast tumours roughly correlated with the occurrence of p53 abnormalities in the respective subsets of tumours, with most p53 aberrations seen among the BRCA1-associated familial tumours and ER/PR/ ERBB2-triple-negative breast carcinomas (Figure 8 ). These results are consistent with the idea that p53 is activated as a downstream effector of the DDR machinery in the incipient cancer cells, in our clinical material therefore presumably in the BRCA1-and ER/PR/ERBB2-triple-negative lesions, at the same time providing a barrier to tumour progression and pressure to select for p53 mutations in those lesions that should eventually progress towards full malignancy, the stage examined in our present study. As indicated by our data on variable expression of gH2AX among the clinical specimens (we did not find any general correlation between MRN defects and the gH2AX marker, data not shown), supported by the response of the MRN-defective A-TLD cells to ionizing radiation (Figure 7) , histone H2AX can be phosphorylated even in cells defective for the MRN complex, also consistent with the data on NBS1-defective cells and the ability of the ATR and DNA-PK kinases which are less dependent on MRN than the ATM kinase (Falck et al., 2005; Shiloh, 2006) to perform this function in at least partially redundant manner. Overall, our results indicate the presence of endogenous DNA damage and ongoing DNA damage signalling in invasive breast tumours, however the signalling may be mostly futile at such advanced stages of cancer progression, due to downstream defects in the DDR machinery such as p53 mutations.
Mechanistically, an interesting aspect of the present analysis is the protein destabilization and consequently aberrant reduction or loss of the MRN complex proteins as a consequence of MRE11 mutations. The coordinated protein instability of MRE11, RAD50 and NBS1 in the MRE11-mutant A-TLD1 and A-TLD2 cells was already reported (Stewart et al., 1999; Uziel et al., 2003) , as was the selective NBS1 protein defect in NBS1-mutant cells (reviewed in Stracker et al., 2004 ; see also Figure 6 in this study). An interesting novel aspect of our present work is the unexpected gross destabilisation of NBS1 in cells with more subtle defects in MRE11, which presumably preserve partial complex of MRE11 with RAD50 and their overall abundance, as documented here by the HCT116 cancer cell line ( Figure 6C ). These results imply that at least in some tumours with aberrantly reduced NBS1 expression, the actual genetic defect may reside in MRE11 rather than NBS1 itself. As the type of intron mutations present in the HCT116 colon cancer cell line reflects defective mismatch repair (Giannini et al., 2002 (Giannini et al., , 2004 Wen et al., 2008) , an abnormality that is particularly common among carcinomas of the colon and uterus, it might be rewarding to search for such MRN protein defects in these types of tumours (Giannini et al., 2004) , and correlate the results with responses to DNA damaging therapy. In any case, it appears that the relatively simple immunohistochemical detection of MRN complex protein aberrations may prove useful in clinical oncology.
Last but not least, our present data point to the intriguing possibility to apply the knowledge about the status of the genome maintenance pathways in an attempt to predict patients' response to common treatment modalities including ionizing radiation and chemotherapy. Our finding that NBS1 deficiency predicts poor survival of the breast cancer patients ( Figure 4D) is consistent with such a notion. In addition, a recent study reported that intact MRN complex status predicts favourable response to radiotherapy in early stages of breast cancer (Soderlund et al., 2007) . On the other hand, available data on individual markers such as the p53 mutation status in relation to treatment resistance are currently controversial, and combinations of p53 with additional, newly discovered markers such as the NQO1 variants, for example (Fagerholm et al., 2008) may eventually provide more reliable sets of predictive markers for diverse clinical settings. This notion is even more relevant considering the attempts in recent years to develop and apply in the clinic small molecule inhibitors of the DDR signalling kinases (Zhou and Bartek, 2004) and possibly other regulatory steps in the DDR machinery. In any case, better knowledge of the genome maintenance mechanisms and impact of their modulation on response to traditional cancer therapies, as well as introduction of novel targeted therapies exemplified by PARP inhibitors promising for treatment of BRCA1/2-defective breast and ovarian cancers (Bryant et al., 2005; Farmer et al., 2005) will likely have a great impact in the upcoming era of individualized medicine.
4.
Experimental procedures
Tumour arrays
Paraffin embedded tissue blocks of the primary carcinomas from unselected and familial breast cancer patients were collected. The unselected breast cancer patient series of 884 incident cases has been collected at the Department of Oncology in 1997 -1998 and described in detail (Syrjä koski et al., 2000 Kilpivaara et al., 2005) . Tumour material from the familial breast cancer patients was collected as described in Eerola et al. (2005a,b) . Apart from the data obtained from pathology records, all tumours were additionally re-reviewed for histological grade and tumour type by one pathologist (P.H.). Grading was performed according to Scarff-BloomRichardson modified by Elston and Ellis (1991) . The most representative area of the tumours was punched to produce breast cancer tissue microarrays (TMA) including four cores (diameter 0.6 mm) from each of the original blocks as previously described (Eerola et al., 2005a,b; Tommiska et al., 2005) . The TMAs included altogether 1335 invasive breast carcinomas, including 921 from familial patients (577 from families with three or more first or second degree relatives with breast or ovarian cancer, including the proband, and 344 from families with two affected first-degree relatives) and 414 from sporadic patients (patients without the abovedefined family history of breast or ovarian cancer). Fifty-two of the tumours from familial patients were from patients in BRCA1 mutation positive families and 56 tumours were from patients in BRCA2 mutation positive families. BRCA1/2 mutation screening was done either by screening of the entire coding regions and exon-intron boundaries using protein truncation test (PTT) and denaturing gradient gel electrophoresis (DGGE), or as previously described (Vehmanen et al., 1997; Vahteristo et al., 2001 Vahteristo et al., , 2002 . Altogether 655 familial tumours were from families for which BRCA1 and BRCA2 mutations had been excluded (including all cases with strong family history) and 158 tumours were from families for which the BRCA1 and BRCA2 mutation status was unknown (families with two affected cases). Permissions for this study were obtained from the Ethics Committee (E8) of the Helsinki University Central Hospital and from the Ministry of Social Affairs and Health in Finland. Blood and tumour samples were used in this study with written informed consent from probands and family members.
Immunohistochemical analysis
For immunohistochemistry, the TMA slides were deparaffinized and processed for sensitive immunoperoxidase staining with the primary mouse monoclonal antibody against human RAD50 (clone 2C6, Abcam, 1:500 dilution), rabbit antibody #4895 against MRE11 (Cell Signaling, diluted 1:1500) and #3002 against NBS1 (Cell Signaling, diluted 1:100), incubated overnight, followed by detection using the Vectastain Elite kit (Vector Laboratories, Burlingame, CA, USA) as previously described (Lukas et al., 2001; Tommiska et al., 2008) . Given that around 95% of epithelial cells were reproducibly and strongly positive on sections of normal breast, we regarded as an aberrant decrease when the protein was detectable in fewer than 70% of cancer cells in a particular lesion, and the staining intensity of the remaining positive cancer cells was reduced compared with normal cells present on the same section. The results were scored as follows: 1 ¼ reduced intensity of staining of carcinoma cells, 2 ¼ reduced number of carcinoma cells with positive staining, 3 ¼ reduced intensity of staining of carcinoma cells and reduced number of carcinoma cells with positive staining, 4 ¼ normal staining of carcinoma cells. The gH2AX marker was detected as described (Bartkova et al., 2005b ) using a phosphospecific antibody from Upstate Biotechnology (USA), and the positivity scored as negative (0-1% positive cells), low (2-10%), medium (11-50%) or high (more than 50% stained cell), consistent with analyses of other types of cancer (Bartkova et al., 2005a) . p53 protein expression in tumours on TMAs was studied as previously described (Bartek et al., 1991; Tommiska et al., 2005) . Briefly, the TMA slides were stained with a mouse monoclonal anti-human p53-antibody DO-7 (Vojtesek et al., 1992) purchased from Dako (Glostrup, Denmark). Samples were considered positive when 20% or more of the cancer cells were positive for the p53 staining.
ERBB2 protein expression was analysed by immunohistochemical staining and ERBB2 gene amplification with chromogenic in situ hybridization (CISH), as previously described . The ERBB2 amplification was considered negative with 2-5 copies of ERBB2 in single nucleus and positive with >6-10 copies. When CISH result was not available, unambiguous immunohistochemistry result (weak/negative staining or strong positivity >90% of cells) was used.
Mutation analysis
The genomic DNA of eight patients with breast tumours with aberrant expression of all the three MRN complex genes was sequenced to search for germline mutations. The coding regions and intron-exon boundaries of RAD50, NBS1 and MRE11 were bidirectionally sequenced using the BigDyeTerminator Cycle Sequencing Kit and an ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA). Primers and conditions are available on request. The two identified variants of MRE11, c.604 A>G Arg202Gly in exon 7 and c.1897 C>T Arg633STOP in exon 17, were also screened in additional 332 patients with strong family history of breast cancer as well as in 363 healthy female control subjects from the same geographical region. Both variants were screened with restriction fragment length polymorphism (RFLP) analysis using suitable restriction enzymes (New England BioLabs, Beverly, MA, USA): for c.604 A>G Arg202Gly BsmFI, which cuts on only the PCR product with G allele, was used; for c.1897 C>T Arg633STOP a mutagenesis PCR-primer was designed that creates a restriction site for FauI, which is abolished by the c.1897 C>T change. Carriers of the c.604 A>G or c.1897 C>T change could be detected in a 3% agarose gel after BsmFI or FauI digestion of the PCR-products, respectively. Additionally, the coding sequence and intron-exon boundaries of NBS1 of seven patients with tumours aberrant for only NBS1 expression, were analysed using conformation sensitive gel electrophoresis, CSGE (Ganguly, 2002) . Genomic DNA from cases showing mobility shifts on CSGE was bidirectionally sequenced.
Statistical analysis
Statistical analysis was conducted with SPSS version 12.0.1 for Windows (SPSS Inc., Chicago, IL, USA). The differences in dichotomous variables were tested by the chi-square test or Fisher's exact test. Univariate analyses of survival were performed by calculating Kaplan-Meier survival curves and comparing subsets of patients using log-rank test. All p-values are two-sided and due to multiple testing, p < 0.01 was considered significant.
4.5.
Cell culture, ionizing radiation treatment, and gene transfer All human cancer cell lines (osteosarcoma line U2OS, and colon cancer cell lines HCT116, SW620 and HT29) were cultured in standard DMEM medium with 10% foetal bovine serum and antibiotics, as described (Aagaard et al., 1995) .
Human fibroblasts from a healthy donor (strain BJ) or from patients with either the A-TLD syndrome (A-TLD1 and A-TLD2) or NB syndrome (NBS-Tert and NBS-1LBI) were grown in DMEM as reported previously (Falck et al., 2002; Horejsi et al., 2004) .
Lymphoblasts from a healthy donor (T476) and from an A-TLD patient (A-TLD3) were grown in medium RPMI-1640 supplemented with 10% foetal bovine serum and antibiotics. All cell culture reagents were from Gibco Invitrogen (USA).
For some experiments, cultured cells were exposed to a dose of 4 Gy of ionizing radiation, delivered by an X-ray generator (HF160, Pantak; 150 kV; 15 mA) at the dose rate 2.18 Gy/min, and analysed at the indicated times after irradiation.
Human HCT116 cells were co-transfected with the plasmid pcDNA3.1MRE11-GFP (encoding the full-length wild-type human MRE11 fused with the Green Fluorescence Protein) together with pBABEpuro at the ratio 5:1, using the FuGene 6 reagent (Roche) according to manufacturer's protocol. Stable transfected clones expressing the transgene were selected in standard DMEM medium with added puromycin (1 mg/ml).
4.6.
Immunofluorescence staining and confocal microscopy Antibodies specific for MRE11, RAD50, NBS1 and gH2AX were identical with those listed in Section 4.2, and a mouse monoclonal antibody to 53BP1 (Schultz et al., 2000) was a gift from Thanos Halazonetis (University of Geneva). Cells grown on glass coverslips were fixed for 15 min in 4% formaldehyde and permeabilized in 0.2% Triton X-100 for 5 min. In some experiments, pre-extraction buffer was used to facilitate visualization of the chromatin bound pools of the MRN proteins, and the detection performed by sensitive immunofluorescence using secondary antibodies coupled to Alexa 488, 568 or 647 (Invitrogen), as described in detail previously (Lukas et al., 2004a) .
Stained coverslips were mounted onto glass slides using a DAPI-containing medium (Vector Laboratories) and subjected to two-or three-colour confocal microscopy on an LSM-510 (Carl Zeiss, Germany) on an Axiovert 100M equipped with Plan-Neofluar oil immersion objectives, as described (Bekker-Jensen et al., 2005 , 2006 .
4.7.
Protein extraction, gel electrophoresis and Western blotting Cells were lysed on ice directly in culture Petri dishes for 20 min, using the following lysis buffer: 50 mM Tris pH 7.5, 150 mM NaCl, 0.5% Igepal 360, 1 mM NaF, 1 mM EDTA, 1 mM PMSF, 10 mM b-glycerophosphate, 1 mg/ml aprotinin, 1 mg/ml leupeptin. After centrifugation (10 min/16,000 Â g/5 C), the supernatant was used, upon estimation of protein concentration with the Bradford method. Conditions for denaturing polyacrylamide gel electrophoresis (using 7.5% separation gel) and Western blotting procedure were essentially as described (Santoni-Rugiu et al., 2000) . The following antibodies were used to detect the proteins transferred to nitrocellulose membrane (Advantec, Japan): mouse monoclonal antibodies to NBS1 (1D7, GeneTex), RAD50 (13B3, GeneTex) and Cdk7 (Tassan et al., 1994) , and rabbit antibodies to MRE11 (NB100-142, Novus Biologicals) and SMC1 (ab9262, Abcam). Secondary antibodies were from Pierce Chemical Co. (Rockford, IL).
